FDA approval is an important milestone, but it is patient adoption that ultimately determines a therapy's commercial success. The company we are profiling today has shown strong early market traction, securing a leading position in the menin inhibitor class within just its second full quarter after launching its acute myeloid leukemia (AML).
Can Komzifti's Early Adoption Support Kura Oncology's Next Phase Of Growth?
